2024年11月19日，中国上海。通和毓承宣布晋升合伙人华尔东先生、朱怡波女士及谢沁博士为管理合伙人，并已于2024年9月生效。

华尔东

华尔东先生于 2012 年作为初创成员加入通和资本，常驻上海办公室。在过去的12年里，华尔东先生主导并参与完成了多项在生物科技、医疗器械和医疗服务领域内的交易，包括杰成医疗、信达生物(1801.HKEX)、华领医药(2552.HKEX)、康泰生物(300601)、国科恒泰(301370)、东软医疗、亘喜生物(GRCL.Nasdaq)、亿康医学、熙康云医院(9686.HKEX)、东软智睿、Grail、慕宝盛科、晟临生物等。此外，华尔东先生作为核心成员参与并负责了通和毓承多支人民币基金的募集设立并担任多支基金的投资决策委员会委员。作为上海办公室负责人，华尔东先生在创始管理合伙人兼首席执行官陈连勇博士领导下，还全面负责上海办公室团队的日常运营和管理，为基金的发展壮大做出了卓越贡献。

朱怡波

朱怡波女士于 2014 年加入通和资本，常驻上海办公室。在过去的 10 年间，朱怡波女士成功主导并参与了基金在医疗器械领域内的多项交易，其中包括少数股权投资如诺美新创、以心医疗、智光科技、瑞尔通等，以及孵化创建整合型投资如泓懿医疗、即通医疗、阿尔法迈士等，明确了基金在医疗器械领域内的投资策略，并不断完善其投资版图。朱女士还深度参与了通和毓承多支人民币基金的发起设立、担任投资决策委员会委员。作为基金负责在医疗器械领域投资的合伙人，朱女士为整个基金在该垂直领域内的战略布局、对外合作、人才引进和投资活动方面所做的积极贡献，得到了基金合伙人和投资人的一致高度评价。

谢沁

谢沁博士于 2016年加入毓承资本，常驻上海办公室。谢沁博士多年来专注于在创新药/技术平台领域由基金主导发起的从零到一的孵化创建型投资，并作为核心成员先后参与和主导了多项在行业内有广泛影响力的创建孵化型投资项目，包括欧康维视(1477.HKEX)、科笛生物(2487.HKEX)、翼思生物、通瑞生物、年衍生物、腾盛博药(2137.HKEX)、基石药业（2616.HKEX）、同宜生物等。在这些孵化创建型投资项目中，谢沁博士倾注了大量的心血精力，同时在公司战略布局、产品引进/合作、人才引进、产业资源落地、公司项目对外合作及并购等方面均发挥着重要而关键的作用，得到共同投资人和企业高管等多方的充分认可。未来谢沁博士会在孵化创建领域继续深耕，并且帮助孵化公司/被投企业积极探索不同方向的国内外合作。除孵化投资外，谢沁博士亦深度参与多支人民币基金的发起设立、担任投资决策委员会委员。

在晋升为管理合伙人后，华尔东先生、朱怡波女士和谢沁博士将继续协助基金创始管理合伙人兼首席执行官陈连勇博士，在持续变动的市场环境中不断优化投资策略并积极践行投资活动，同时深入参与基金的日常运营和管理，共同推动基金的发展迈向下一个崭新阶段。

November 18, 2024, Shanghai China. 6 Dimensions Capital announced the Managing Partner promotion of Erdong Hua, Rebecca Zhu, Qin Xie, effective in September, 2024.

Erdong Hua

Erdong joined Frontline in 2012, and is based in Shanghai office. During the past 12 years, Erdong has accomplished large numbers of deals covering Biotech, Medtech and Medical Service, such as Celest, Mabsoft, Solvo, BioKangtai, Neusoft Medical, GKHT, Neusoft Xikang, Gracell, etc. In addition, Erdong has made great contribution to closing RMB fund through his professionalism and strong sense of responsibility. In the meanwhile, as the site manager of Shanghai office, Erdong consistently put a lot of efforts into office daily operations and management. 

Rebecca Zhu

Rebecca joined Frontline in 2014, and is based in Shanghai office. Over the past 10 years, Rebecca has led a number of medtech deals, including minority investment such as Nanos Medical, Mitrassist, WiseTek, Realton and etc., as well as NewCo incubation and integration such as Hua Medtech, VFLO Medical, Alfa Medtech and etc., and has been responsible for setting up investment strategy for medtech sector in general. She also has been heavily involved in RMB fund raising. Thanks to her devoted endeavor and strong expertise, she is also highly appraised by portfolio companies, LPs and co-investors. 

Qin Xie

Qin joined WXHV in 2016, and is based in Shanghai office. Qin has been focusing on NewCo formation/incubation opportunities across various therapeutics areas (TA) as well as modality platform NewCo. She has led the incubation work in Ocumension (1477 HKEX), Cutia (2487 HKEX), Ignis, C-Ray, Nicoya, Brii (2137 HKEX), CStone (2616 HKEX) and Coherent. She has been putting tremendous efforts and plays key role from many perspectives, including NewCo strategic planning, in-licensing/out-licensing, talents retention, collaboration and M&A etc. Despite all the difficulties and challenges, she has been making every effort to help companies to reach each milestone. In the future, she will continue to cultivate NewCo incubation ideas as well as proactively help NewCo/portfolio companies to explore different opportunities in global collaboration. Qin has demonstrated excellent capability in maintaining relationship and dealing with different stakeholders, and in the meanwhile, she has also acted as a key contributor to 6DC's RMB fund raising in the past 4 years.

As the Managing Partner, Erdong, Rebecca and Qin will continue to work with CEO to shape our investment strategy, and deeply involved in the fund’s daily operations and management. Trust that they will lead the corresponding portfolio companies to move forward to the next stage by collaboration with internal and external stakeholders.

关于通和毓承

通和毓承是一家专注于医疗健康领域投资的全球化公司，目前在波士顿，旧金山，香港及上海均设有办公室。公司专注于在欧美、中国、以色列等全球范围投资医疗健康领域初创期及成长期阶段的公司。我们赋能企业家，帮助他们创建创新性医疗健康业务，造福全球患者。

了解更多有关通和毓承的信息，请登陆网站:www.6dimensionscapital.com。